Results 101 to 110 of about 557 (132)
Some of the next articles are maybe not open access.
Diabetes, 2023
Combining sema (semaglutide 2.4 mg) and amylin analog cagri (cagrilintide 2.4 mg) has weight loss benefits, but the impact on HbA1c is unknown. This study is the first to assess the efficacy and safety of CagriSema (co-administered) vs sema or cagri alone in participants (pts) with T2D.
JUAN P. FRIAS +8 more
openaire +1 more source
Combining sema (semaglutide 2.4 mg) and amylin analog cagri (cagrilintide 2.4 mg) has weight loss benefits, but the impact on HbA1c is unknown. This study is the first to assess the efficacy and safety of CagriSema (co-administered) vs sema or cagri alone in participants (pts) with T2D.
JUAN P. FRIAS +8 more
openaire +1 more source
Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes
New England Journal of MedicineCagrilintide and semaglutide have each been shown to induce weight loss as monotherapies. Data are needed on the coadministration of cagrilintide and semaglutide (called CagriSema) for weight management in adults with type 2 diabetes, including those in a subgroup who are undergoing continuous glucose monitoring.In this phase 3a, double-blind ...
Carel le Roux +2 more
exaly +3 more sources
Life SciencesCagrilintide (also known as 0833) is an amylin and calcitonin receptor agonist in clinical development for weight management and type-2-diabetes in a fixed-dose combination with semaglutide. Here, we introduce 0174-0839 (0839) as a tool compound for mouse and rat in vivo and in vitro studies of amylin analogues such as cagrilintide.
Sanaz Gabery +2 more
exaly +3 more sources
Diabetes, 2023
Continuous glucose monitoring (CGM) offers insight into glycemic levels beyond the conventional measurement of HbA1c. This phase 2, multicenter, 32-week, double-blind trial (NCT04982575) compared the effects of CagriSema (co-administered semaglutide [sema] 2.4 mg and cagrilintide [cagri] 2.4 mg) vs sema (2.4 mg) or cagri (2.4 mg) alone, all as once ...
CHANTAL MATHIEU +8 more
openaire +1 more source
Continuous glucose monitoring (CGM) offers insight into glycemic levels beyond the conventional measurement of HbA1c. This phase 2, multicenter, 32-week, double-blind trial (NCT04982575) compared the effects of CagriSema (co-administered semaglutide [sema] 2.4 mg and cagrilintide [cagri] 2.4 mg) vs sema (2.4 mg) or cagri (2.4 mg) alone, all as once ...
CHANTAL MATHIEU +8 more
openaire +1 more source
Acta Pharmacologica SinicaThe global obesity epidemic and its associated metabolic disorders urgently require more effective therapeutic interventions, particularly multi-pathway targeting therapies. Cagrilintide (Cagri), functioning as a dual amylin receptor (AMYRs) and calcitonin receptor (CTR) agonist (DACRA), demonstrates significant efficacy in obesity treatment, although ...
Huaqiang Xu, Li-Hua Zhao
exaly +3 more sources
Diabetes, 2023
Background: Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) and sodium-glucose co-transporter-2 inhibitors (SGLT2i) demonstrated cardiovascular (CV) and kidney outcomes benefit in persons with type 2 diabetes (T2D). The long-acting amylin analogue, cagrilintide, is under investigation for the treatment of obesity and T2D.
ALEXANDRA MØLLER +7 more
openaire +1 more source
Background: Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) and sodium-glucose co-transporter-2 inhibitors (SGLT2i) demonstrated cardiovascular (CV) and kidney outcomes benefit in persons with type 2 diabetes (T2D). The long-acting amylin analogue, cagrilintide, is under investigation for the treatment of obesity and T2D.
ALEXANDRA MØLLER +7 more
openaire +1 more source
The Innovation Medicine
<p>The escalating global burden of obesity and type 2 diabetes (T2D) necessitates highly effective therapies. The novel fixed-dose combination Cagrilintide-Semaglutide (CagriSema), merging a GLP-1 receptor agonist (Semaglutide) with an amylin analog (Cagrilintide), represents a significant therapeutic advance.
Zhien Feng
exaly +2 more sources
<p>The escalating global burden of obesity and type 2 diabetes (T2D) necessitates highly effective therapies. The novel fixed-dose combination Cagrilintide-Semaglutide (CagriSema), merging a GLP-1 receptor agonist (Semaglutide) with an amylin analog (Cagrilintide), represents a significant therapeutic advance.
Zhien Feng
exaly +2 more sources
#2426 Exploration of cagrilintide's mechanism of action in the kidney
Nephrology Dialysis TransplantationAbstract Background and Aims The hormone amylin, co-secreted with insulin from the beta-cells of the pancreas, induces satiety. Previous studies have highlighted a physiological role of amylin in glucose/sodium homeostasis and blood pressure regulation.
Vera Wulfmeyer +4 more
openaire +1 more source
Exploration of Cagrilintide's Mechanism of Action in the Kidneys
Journal of the American Society of Nephrology: JASNVera Christine Wulfmeyer +4 more
exaly +2 more sources